DataString Consulting Company Logo
DataString Consulting Company Logo
Piflufolastat F 18 Market
Home»Top Market Reports»Piflufolastat F 18 Market

Piflufolastat F 18 Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802126, Published - March 2025

Segmented in Application Scope (Prostate Cancer, Breast Cancer, Lung Cancer, Others), End-users (Research Institutes, Hospitals, Diagnostic Centers, Others), Treatment Procedure, Distribution Channel and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Piflufolastat F 18 Market Outlook

The market, for Piflufolastat f 18 was estimated at $412.2 million in 2024; and it is anticipated to increase to $625.6 million by 2030 with projections indicating a growth to around $885.6 million by 2035. This expansion represents a compound annual growth rate (CAGR) of 7.2% over the forecast period. The significant growth of the Piflufolastat F 18 market is driven by key factors; a notable increase in prostate cancer cases worldwide leading to a higher demand for accurate diagnostic methods and the continuous progress in medical technology, like oncology isotopes facilitating their use. The creation of agents such, as Piflufolastat F 18 is increasingly acknowledged as essential because of their non invasive characteristics which have enhanced the safety and accuracy of diagnostics and thereby supporting the continuous significance and expansion of the market.


The medical radioactive tracer known as Piflufolastat F 18 is gaining recognition in the healthcare industry for its effectiveness in targeting prostate cancer cells with precision and accuracy due to its characteristics like high sensitivity and specificity. Its applications, in positron emission tomography (PET) scans have proven to be significant and valuable.


Market Size Forecast & Key Insights

2019
$412M2024
2029
$826M2034

Absolute Growth Opportunity = $414M

The Piflufolastat F 18 market is projected to grow from $412.2 million in 2024 to $826 million in 2034. This represents a CAGR of 7.2%, reflecting rising demand across Prostate Cancer Diagnosis, Post Treatment Evaluation and Recurrence of Prostate Cancer.

The Piflufolastat F 18 market is set to add $414 million between 2024 and 2034, with manufacturer targeting Hospitals & Diagnostic Centers End-users projected to gain a larger market share.

With Anticipated advancements in healthcare increased medical imaging, and Rise in cancer cases urgent need for early detection, Piflufolastat F 18 market to expand 100% between 2024 and 2034.

Opportunities in the Piflufolastat F 18 Market

Untapped Theranostic Application

Piflufolastat F 18, primarily known for its diagnostic applications in oncology, holds substantial potential in theranostics a rapidly growing field that integrates therapy and diagnostics. This hybrid approach could revolutionize personalized medicine, facilitating accurate diagnosis and subsequent therapy. Piflufolastat F 18s unique property of binding to prostate-specific membrane antigen can potentially be exploited for this combined approach to fight prostate cancer. A theranostic application using Piflufolastat F 18 could offer an effective tool in managing the disease, offering huge market potential that has yet to be completely explored.

Growth Opportunities in North America and Asia-Pacific

Asia Pacific Outlook

The Asia Pacific region is showing growth potential as a promising market for Piflufolastat F 18 due to increased investments in healthcare innovation and a growing elderly population with higher cancer rates awareness of the benefits of early detection is also on the rise The need for more advanced tools for cancer diagnosis is boosting market opportunities in this region Moreover the market expansion is being fueled by the expected increase, in PET scan usage rates as healthcare professionals aim to enhance patient outcomes Furtheremore top firms from both global markets are fueling competition, in the region to make the most of these emerging opportunities.

North America Outlook

In North America's medical imaging industry where Piflufolastat F 18 thrives as a profitable market segment the regions leadership is attributed to significant progress in healthcare technology and the rise of biopharmaceutical innovations. A key advantage is its state of the art healthcare system that showcases growing integration of cutting edge equipment like PET scanners equipped with Piflufolastat F 18. Moreover the competitive landscape, with players fuels market competition and spurs on creativity within this geographical region. The increasing need for diagnostic options remains high, in the field of cancer detection. This trend is driving market expansion and opening up prospects for those involved in the industry.

North America Outlook

In North America's medical imaging industry where Piflufolastat F 18 thrives as a profitable market segment the regions leadership is attributed to significant progress in healthcare technology and the rise of biopharmaceutical innovations. A key advantage is its state of the art healthcare system that showcases growing integration of cutting edge equipment like PET scanners equipped with Piflufolastat F 18. Moreover the competitive landscape, with players fuels market competition and spurs on creativity within this geographical region. The increasing need for diagnostic options remains high, in the field of cancer detection. This trend is driving market expansion and opening up prospects for those involved in the industry.

Asia-Pacific Outlook

The Asia Pacific region is showing growth potential as a promising market for Piflufolastat F 18 due to increased investments in healthcare innovation and a growing elderly population with higher cancer rates awareness of the benefits of early detection is also on the rise The need for more advanced tools for cancer diagnosis is boosting market opportunities in this region Moreover the market expansion is being fueled by the expected increase, in PET scan usage rates as healthcare professionals aim to enhance patient outcomes Furtheremore top firms from both global markets are fueling competition, in the region to make the most of these emerging opportunities.

Growth Opportunities in North America and Asia-Pacific

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Germany, China, Japan, Canada are expected to grow at 4.7% to 6.9% CAGR

2

Emerging Markets : Brazil, South Africa, India are expected to grow at 8.3% to 9.9% CAGR

Market Analysis Chart

The market for Piflufolastat F 18 within the nuclear medicine industry is influenced by factors that shape its growth path significantly. One key factor driving growth is the increasing incidence of prostate cancer necessitating diagnostic tools such as Piflufolastat F. Additionally the progress in nuclear imaging technology and favorable results from trials have strengthened its position, in the market.

Recent Developments and Technological Advancement

December 2024

PharmaStar Inc introduced a cutting edge diagnostic method that utilizes Piflufolastat F 18 to anticipate the development of prostate cancer, in its early stages.

October 2024

HealthScope Pharmaceuticals has revealed plans to expand their manufacturing facilities in order to produce Piflufolastat F 18 and reach a wider market while meeting the growing demand.

July 2024

Bio Med Solutions announced a collaboration with QuickRad Diagnostics to enhance the research and development of Piflufolastat F 18. The focus is on enhancing the accuracy of scans, for detecting cancer.

in the field of medical imaging technology a new radiopharmaceutical called Piflufolastat F 18 has been making waves. This innovative substance is used in Philips PET/CT scans to help identify recurring cases of prostate cancer with accuracy. The potential of this compound is quite promising with the growing dependence on cutting edge medical tools, for diagnosing illnesses nowadays.

Impact of Industry Transitions on the Piflufolastat F 18 Market

As a core segment of the Pharmaceutical industry, the Piflufolastat F 18 market develops in line with broader industry shifts. Over recent years, transitions such as Advancements in Cancer Diagnostics and Strategic Shift towards Personalized Care have redefined priorities across the Pharmaceutical sector, influencing how the Piflufolastat F 18 market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Advancements in Cancer Diagnostics:

The Piflufolastat F 18 or Axumin represents a progress in the field of cancer detection. It serves as a substance for PET scans This medical breakthrough has improved the accuracy and effectiveness in detecting recurring prostate cancer—a significant advantage, for both doctors and patients. By pinpoint the regions in the body that could go unnoticed in regular MRI or CT scans Piflufolastat F 18 greatly enhances the early detection and planning of treatment for prostate cancer showcasing the impactful possibilities of cutting edge diagnostic tools, in healthcare.

2

Strategic Shift towards Personalized Care:

The advancement and utilization of diagnostic substances like Piflufolastat F 18 signify a widespread transition in the medical field towards individualized treatment rather than a uniform approach for all patients. This customized method is especially prominent, in cancer therapy where distinct genetic characteristics of a patients cancer can be pinpointed for personalized treatment.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Piflufolastat F 18 market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Anticipated Advancements in Healthcare Increased Medical Imaging, and Favorable Regulatory Scenario Streamlined Approvals

The rapid progress in the field of healthcare is also anticipated to have also an impact in boosting the need for Piflufolastat F 18 as a vital tool for detecting prostate cancer early in patients journey, towards recovery and treatment options.
The market expansion of Piflufolastat F 18 is also projected to see a boost due to positive regulatory conditions related to drug endorsements as well as quicker approval processes for radiopharmaceuticals by entities such as the FDA which are also propelling market growth by facilitating swift patient access to vital diagnostic tools, like Piflufolastat F 18.
Prostate cancer is also becoming increasingly common worldwide and early detection is also crucial for treatment strategies to be implemented quickly and accurately using Piflufolastat F 18 in advanced imaging techniques such, as PET scans to detect cancer cells promptly and accurately and drive market expansion.

Restraint: Regulatory Hurdles

The primary obstacle arises from regulatory barriers that pose challenges for the widespread adoption of Piflufolastat F 18 in the healthcare industry as it belongs to the category of radiopharmaceutical products subject to stringent regulations by health authorities globally. Companies encounter delays in obtaining approvals with minor deviations risking significant penalties. The process from conducting trials to launching the product in the market is intricate and slow moving due to regulatory complexities. thereby affecting the time, to market and influencing consumer demand trends.

Challenge: High Production Cost

One significant market factor is the cost of producing Piflufolastat F 18 due, to the complex manufacturing process involved in making radiopharmaceutical products requiring precision and standardization that naturally leads to increased expenses.

Supply Chain Landscape

Raw Material Procurement

Advanced BioChemicals

PharmCo Labs

API Synthesis

Global PharmaTech

SynthoChem LLC

Production
Radiant Pharmaceuticals / TraceLife Sciences
Distribution & Marketing
Progenics Pharmaceuticals / Lantheus Medical Imaging
Raw Material Procurement

Advanced BioChemicals

PharmCo Labs

API Synthesis

Global PharmaTech

SynthoChem LLC

Production

Radiant Pharmaceuticals

TraceLife Sciences

Distribution & Marketing

Progenics Pharmaceuticals

Lantheus Medical Imaging

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Prostate Cancer Detection
Radiopharmacology
Telix Pharmaceuticals
Product diversification and global reach
Biomedical Research
Biopharmaceuticals
Blue Earth Diagnostics
Clinical functionality research and scientific partnerships
Disease Progression Monitoring
Diagnostic Imaging
Progenics Pharmaceuticals
Investment in technological advancements and proprietary diagnostic versatility
Lesion Localization
Clinical Oncology
Novartis
Integration with established diagnostics and tailored treatment planning

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Piflufolastat F 18 market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Piflufolastat F 18 in Post Treatment Evaluation, Recurrence of Prostate Cancer and Prostate Cancer Diagnosis

Post Treatment Evaluation

Piflufolastat F 18 plays a part not only in diagnosing and detecting recurring prostate cancer but also in assessing patients after treatment.

Recurrence of Prostate Cancer

Medical professionals commonly use a substance called Piflufolastat F 18 to identify recurring prostate cancer cases accurately. The unique properties of this radiotracer allow it to attach to cells that express PSMA leading to imaging of cells affected by recurrent or spreading cancer. This tool has been crucial in guiding the selection of treatment methods and has played a significant role in managing the progression of the disease. Respected companies like Progenics Pharmaceuticals showcase their expertise in utilizing this substance for such purposes and solidifying their position, in the industry.

Prostate Cancer Diagnosis

Piflufolastat F 18, widely recognized in the medical community as an innovative diagnostic compound, is extensively utilized in prostate cancer detection. This radiopharmaceutical drug is attributed with the unique ability to visualize prostate specific membrane antigen -expressing prostate cancer cells. Therefore, its successful use in PSMA PET imaging substantially enhances the accuracy of prostate cancer diagnosis, offering potentially earlier detection and more precise treatment strategies. Renowned industry players harnessing the potential of Piflufolastat F 18 in this regard include Lantheus Holdings, recognized for their strengths in diagnostic imaging and nuclear medicine.

Piflufolastat F 18 vs. Substitutes:
Performance and Positioning Analysis

Piflufolastat F 18 presents exponential potential for growth, notably excelling in precision, efficacy and safety over its diagnostic radiopharmaceutical counterparts. Its unique market positioning lies in its utilization for advanced prostate cancer detection. These Alternatives specially Fluciclovine F18 has experienced a rapid growth as detailed in our latest report.

Piflufolastat F 18
  • Fluciclovine F18 /
  • RhPSMA 3 /
  • 68Ga PSMA 11
    High diagnostic accuracy in detecting prostate cancer, demonstrated safety and efficacy
    Limited accessibility due to production constraints, higher costs in comparison to traditional diagnostic methods
    Increased sensitivity, broader accessibility
    limited specificity, potential for allergic reactions

Piflufolastat F 18 vs. Substitutes:
Performance and Positioning Analysis

Piflufolastat F 18

  • High diagnostic accuracy in detecting prostate cancer, demonstrated safety and efficacy
  • Limited accessibility due to production constraints, higher costs in comparison to traditional diagnostic methods

Fluciclovine F18 / RhPSMA 3 / 68Ga PSMA 11

  • Increased sensitivity, broader accessibility
  • limited specificity, potential for allergic reactions

Piflufolastat F 18 presents exponential potential for growth, notably excelling in precision, efficacy and safety over its diagnostic radiopharmaceutical counterparts. Its unique market positioning lies in its utilization for advanced prostate cancer detection. These Alternatives specially Fluciclovine F18 has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Piflufolastat F 18 market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Piflufolastat F 18 across Research Institutes, Hospitals, and Diagnostic Centers Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Progenics Pharmaceuticals, Telix Pharmaceuticals, and Blue Earth Diagnostics by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Procurement, API Synthesis, and Production. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Piflufolastat F 18 segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Procurement (Advanced BioChemicals, PharmCo Labs), API Synthesis (Global PharmaTech, SynthoChem LLC), and Production. Our parallel substitute analysis examines Fluciclovine F18, RhPSMA 3, and 68Ga PSMA 11, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Progenics Pharmaceuticals, Telix Pharmaceuticals, and Blue Earth Diagnostics, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Piflufolastat F 18 market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Piflufolastat F 18 Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 441 million
Revenue Forecast in 2034USD 826 million
Growth RateCAGR of 7.2% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024412 million
Growth OpportunityUSD 414 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024412 million USD
Market Size 2027507 million USD
Market Size 2029583 million USD
Market Size 2030625 million USD
Market Size 2034826 million USD
Market Size 2035885 million USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredApplication Scope, End-users, Treatment Procedure, Distribution Channel
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledProgenics Pharmaceuticals, Telix Pharmaceuticals, Blue Earth Diagnostics, Advanced Accelerator Applications, Bayer AG, GE Healthcare, Eli Lilly and Company, Spectrum Pharmaceuticals, RadioMedix Inc, Siemens Healthineers, AstraZeneca and Novartis AG
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Piflufolastat F 18 Market Size, Opportunities & Strategic Insights, by Application Scope

4.1Prostate Cancer
4.2Breast Cancer
4.3Lung Cancer
4.4Others
Chapter 5

Piflufolastat F 18 Market Size, Opportunities & Strategic Insights, by End-users

5.1Research Institutes
5.2Hospitals
5.3Diagnostic Centers
5.4Others
Chapter 6

Piflufolastat F 18 Market Size, Opportunities & Strategic Insights, by Treatment Procedure

6.1PET Scan
6.2Radiology Imaging
Chapter 7

Piflufolastat F 18 Market Size, Opportunities & Strategic Insights, by Distribution Channel

7.1Direct Sales
7.2Indirect Sales
7.3Online Sales
Chapter 8

Piflufolastat F 18 Market, by Region

8.1North America Piflufolastat F 18 Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Piflufolastat F 18 Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Piflufolastat F 18 Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Piflufolastat F 18 Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Piflufolastat F 18 Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Piflufolastat F 18 Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Progenics Pharmaceuticals
9.2.2Telix Pharmaceuticals
9.2.3Blue Earth Diagnostics
9.2.4Advanced Accelerator Applications
9.2.5Bayer AG
9.2.6GE Healthcare
9.2.7Eli Lilly and Company
9.2.8Spectrum Pharmaceuticals
9.2.9RadioMedix Inc
9.2.10Siemens Healthineers
9.2.11AstraZeneca
9.2.12Novartis AG